Canavan disease (CD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Canavan disease (CD) is a genetic
degenerative brain disease caused by a lack of the enzyme aspartoacylase
(ASPA). N-acetylaspartic acid builds up in the brain and other body parts when
ASPA activity is lost. CD is diagnosed by detecting elevated NAA in urine,
blood, or the brain by proton MR spectroscopy and ASPA mutation analysis.
Insufficient myelination and progressive spongy degeneration of the brain's
white matter characterize the disease histologically. While not all Canavan
disease (CD) patients had epilepsy in their early years, seizure prevalence
increased over the first decade, with all CD patients having seizures by ten.
Multiple antispasmodic or antiepileptic drugs are frequently required to treat
neurological symptoms such as seizures and spasticity. Canavan disease (CD) is
caused by mutations in the ASPA gene (17p13.3), which codes for the
aspartoacylase enzyme. Numerous mutations have been discovered, and enzymatic
activity is either low or non-existent as a result.
- The incidence of Canavan disease (CD) varies between 1 to 1.5
cases per 100,000 birth population in the USA.
Thelansis’s “Canavan disease (CD) Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Canavan
disease (CD) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Canavan disease (CD) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Canavan disease (CD) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment